| Name | (S,R,S)-AHPC-PEG2-NH2 hydrochloride | 
| Description | (S,R,S)-AHPC-PEG2-NH2 hydrochloride (E3 ligase Ligand-Linker Conjugates 6) is a synthesized E3 ligase ligand-linker conjugate that includes the (S,R,S)-AHPC based VHL ligand and a 2-unit PEG linker used in the synthesis of PROTAC. | 
| In vitro | PROTACs consist of two ligands joined by a linker: one targets an E3 ubiquitin ligase, and the other targets the desired protein. They harness the intracellular ubiquitin-proteasome system to selectively degrade these target proteins[1]. | 
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | 
| Solubility Information | DMSO : 100 mg/mL (163.35 mM), Sonication is recommended. H2O : 100 mg/mL (163.35 mM), Sonication is recommended.
 
 | 
| Keywords | VHL Ligand-Linker Conjugates 3 Hydrochloride | VHL Ligand-Linker Conjugates 3 | VHL | VH032-PEG2-NH2 Hydrochloride | Inhibitor | inhibit | E3LigaseLigandLinkerConjugate | E3 Ligase Ligand-Linker Conjugates | E3 Ligase Ligand-Linker Conjugate | E3 Ligase LigandLinker Conjugate | AHPC-PEG2-NH2 Hydrochloride | (S,R,S)-AHPC-PEG-2-NH2 hydrochloride | (S,R,S)AHPCPEG2NH2 hydrochloride | (S,R,S) AHPC PEG2 NH2 hydrochloride | 
| Inhibitors Related | Thalidomide-O-amido-PEG2-C2-NH2 TFA | Thalidomide-O-amido-C3-NH2 TFA | Thalidomide-O-amido-C6-NH2 hydrochloride | Thalidomide-O-amido-PEG3-C2-NH2 TFA | Thalidomide 4'-ether-alkylC2-amine hydrochloride | (S,R,S)-AHPC-PEG3-N3 | Thalidomide-NH-C2-PEG3-OH | Thalidomide-NH-C4-NH-Boc | Pomalidomide 4'-PEG3-azide | Thalidomide-O-C6-NH2 hydrochloride | Thalidomide-O-amido-C4-NH2 TFA | Pomalidomide-C2-NH2 hydrochloride |